Advanced glycation end products promote human aortic smooth muscle cell calcification in vitro via activating NF-κB and down-regulating IGF1R expression

Acta Pharmacologica Sinica

Volumn 34, Issue 4, 2013, Pages 480-486

  Wang, Yi ^a   Zhang, Zhen Yu ^a   Chen, Xiao Qing ^a   Wang, Xiang ^a   Cao, Heng ^a   Liu, Shao Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Cbfa1; Human aortic smooth muscle cell; Insulin like growth factor 1 receptor (IGF1R); Nuclear factor kappa B; Osteocalcin; PDTC; Vascular calcification

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALIZARIN RED S; CALCIUM; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOPLASM PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCALCIN; PHOSPHATE; PYRROLIDINE DITHIOCARBAMATE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD VESSEL CALCIFICATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN AORTIC SMOOTH MUSCLE CELL; HUMAN CELL; IN VITRO STUDY; MINERALIZATION; PROMOTER REGION; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE FIBER; SUPERNATANT; WESTERN BLOTTING;

AORTA; CALCIUM; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOWN-REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; I-KAPPA B PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; VASCULAR CALCIFICATION;

EID: 84877244583     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.166     Document Type: Article

References (32)

1. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-42 (Pubitemid 34258697)
2. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-21 (Pubitemid 30410374)
3. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on allcause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40 (Pubitemid 37098542)
4. Reaven PD, Sacks J. Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia 2005; 48: 379-85 (Pubitemid 40543312)
5. Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, et al. Vascular calcification in chronic kidney disease. Clin Sci (Lond) 2010; 119: 111-21
6. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-7 (Pubitemid 39274370)
7. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008; 45: 1-16
8. Chen XF, Lin WD, Lu SL, Xie T, Ge K, Shi YQ, et al. Mechanistic study of endogenous skin lesions in diabetic rats. Exp Dermatol 19: 1088-95
9. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med 1995; 1: 1002-4
10. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28: 419-26 (Pubitemid 26380001)
11. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): A novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008; 14: 487-95 (Pubitemid 351516853)
12. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009; 46: 572-80
13. Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 2011; 91: 537-45
14. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-71 (Pubitemid 27425832)
15. Duer MJ, Friscic T, Proudfoot D, Reid DG, Schoppet M, Shanahan CM, et al. Mineral surface in calcified plaque is like that of bone: Further evidence for regulated mineralization. Arterioscler Thromb Vasc Biol 2008; 28: 2030-4
16. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001; 21: 274-301 (Pubitemid 32565495)
17. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001; 44: 129-46 (Pubitemid 32156196)
18. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009; 16: 845-58
19. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46: 217-24
20. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-Accelerated atherosclerosis. Diabetes 2004; 53: 1813-23 (Pubitemid 38857040)
21. Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 2009; 37: 847-54
22. Yamagishi S, Matsui T. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr Drug Targets 2010; 11: 875-81
23. Wang Z, Jiang Y, Liu N, Ren L, Zhu Y, An Y, et al. Advanced glycation end-product Nepsilon-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012; 221: 387-96
24. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-64 (Pubitemid 27516178)
25. Kavurma MM, Figg N, Bennett MR, Mercer J, Khachigian LM, Littlewood TD. Oxidative stress regulates IGF1R expression in vascular smooth-muscle cells via p53 and HDAC recruitment. Biochem J 2007; 407: 79-87 (Pubitemid 47535583)
26. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-7 (Pubitemid 32539602)
27. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 435-44 (Pubitemid 38326135)
28. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 2008; 75: 1441-50 (Pubitemid 351375180)
29. Kasukawa Y, Baylink DJ, Wergedal JE, Amaar Y, Srivastava AK, Guo R, et al. Lack of insulin-like growth factor I exaggerates the effect of calcium deficiency on bone accretion in mice. Endocrinology 2003; 144: 4682-9 (Pubitemid 37378375)
30. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer L. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 2005; 96: 398-400 (Pubitemid 40354532)
31. Zhu P, Ren M, Yang C, Hu YX, Ran JM, Yan L. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 2012; 21: 123-9
32. Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM, et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012; 82: 34-44